![]() |
Open for inclusion |
A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanomCancer type: Melanoma Phase: I/II Principal Investigator: Nyakas Martha Country: NO Keywords: Norway, Oslo, BGB324, AXL-inhibitor Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02872259?term=Melanoma&recrs=a&type=Intr&cntry1=EU%3ANO&rank=1 |